HeartSciences (HSCS)
Operates a device-agnostic ECG workflow and AI-algorithm marketplace.
Something off on this page? Send us feedback.
Sells ECG workflow software and plans subscription and algorithm-access revenue while developing its own AI-enabled resting ECG system. Its device-agnostic platform works with hospitals’ installed ECG equipment, but clinical algorithms and proprietary hardware depend on applicable regulatory authorization.
Operates MyoVista Insights, a cloud-native platform that collects electrocardiograms from existing machines, manages workflows, and distributes compatible AI algorithms through a marketplace. Revenue is intended to come from implementation fees, subscription usage, and algorithm access; device sales, electrodes, and software support the separate MyoVista wavECG model. The United States is the planned direct-sales market, with distributors intended for markets outside it.
Combines internally developed technology with licenses from Mount Sinai and the University of Glasgow. MyoVista wavECG and the company's clinical algorithms remain subject to FDA authorization for U.S. marketing, while the platform's data-system exemption does not automatically apply to hosted algorithms. The old European CE mark for MyoVista lapsed, limiting proprietary-hardware access there.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
No analyst notes in the last 24 months.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jul 31, 2026Cash & short-term investments $29.9M · Total debt $4.0M · Total assets $3.7M · Shareholders' equity −$2.0M
- Revenue
- $2.1K
- Operating income
- −$2.9M
- Net income
- −$3.2M
No dividends on record.
| Insiders | 23.34% | 504.1K shares | |
|---|---|---|---|
| 2 holders · as of Jun 24, 2026 | |||
| Other | 76.66% | 1.66M shares | |
| remainder | |||
2.16M company shares as of Sep 6, 2026 · holders as of their latest filing
Two share counts disagree (4.80M in the company's Sep 22, 2026 report, 2.16M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Andrew SimpsonInsiderdirector, officer: See Remarks | 23.12% | 499,382 | filed Jun 24, 2026 |
Mark T. HilzInsiderdirector, officer: COO, Secretary and Director | 0.22% | 4,752 | filed Jul 30, 2025 |
Digital Currency Group, Inc.Strategic | —9.40% of class, as filed | — | filed Aug 18, 2026 |
EinInsider | —8.10% of class, as filed | — | filed Dec 11, 2023 |
Fields Ephraim GInsider | —8.10% of class, as filed | — | filed Jun 24, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- GE HealthCare
Broad incumbent in ECG devices, workflow software and interpretation.
- Philips (ADR)
Enterprise ECG workflow rival with multi-vendor access and interpretation.
- Baxter International
Resting ECG hardware, workflow software and consumables rival.
- Tempus AI
FDA-cleared AI algorithms contest 12-lead ECG screening.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| HeartSciences | $4.74 | +1.18% | $10.1M | — | — | — | +10.5% |
| GE HealthCare | $66.19 | +2.14% | $29.27B | 18.8 | 12.7 | 1.4 | +5.8% |
| Philips (ADR) | $25.07 | +0.66% | $24.34B | 18.7 | 13.0 | 1.2 | −2.8% |
| Baxter International | $23.70 | +3.34% | $11.85B | — | 11.2 | 1.0 | +5.3% |
| Tempus AI | $76.89 | −1.47% | $13.67B | — | — | 9.5 | +21.6% |
| Median | 18.8 | 12.7 | 1.3 | +5.6% |